Immunotherapy for GI Malignancies, Ready for Prime Time?

Autor: Tieniber AD; Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Perez JE; Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Hanna AN; Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., DeMatteo RP; Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. dematter@upenn.edu.
Jazyk: angličtina
Zdroj: Annals of surgical oncology [Ann Surg Oncol] 2023 Mar; Vol. 30 (3), pp. 1787-1793. Date of Electronic Publication: 2022 Oct 22.
DOI: 10.1245/s10434-022-12668-w
Abstrakt: Gastrointestinal (GI) cancers include esophageal, gastric, pancreatic, hepatobiliary, and colorectal malignancies. Immunotherapy has proved to be an important treatment method for cancer, and its use for a wide range of GI malignancies has been evaluated recently. This article discusses the type and mechanism of various immunotherapies under investigation in GI cancer. The study also reviews recent clinical trials, with a particular focus on overall survival, and discusses their achievements and limitations. Immunotherapy has shown efficacy for microsatellite instability high colorectal cancer and some promise in some gastroesophageal junction and gastric cancers. Meanwhile, it has not been effective for pancreatic or neuroendocrine tumors. The identification of novel biomarkers likely will guide selection of therapy for individual patients. Nevertheless, immunotherapy for GI cancers is in its infancy, and many other classes of immune therapies are being developed besides anti-PD1 and anti-PDL1. Thus, although immunotherapy has not seen a dramatic advance to date, it still has great potential.
(© 2022. Society of Surgical Oncology.)
Databáze: MEDLINE
Externí odkaz: